Compare Amgen, Inc. (AMGN) vs CSX Corporation (CSX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs CSX Corporation — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while CSX Corporation trades at $49.83 (market cap $91.81B). The key difference: Amgen, Inc. is far larger — about 2.1× CSX Corporation's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | CSX | |
|---|---|---|
Market Cap | $196.12B | $91.81B |
Sector | Health | Industrials |
52-Week High | $388.16 | $49.41 |
52-Week Low | $271.18 | $32.05 |
Enterprise Value | $241.41B | $110.04B |
Dividend Yield | 2.77% | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
CSX trades at $49.41, slightly above the consensus price target of $48.21, with a 0.12% daily gain. The technical outlook is bullish based on moving averages, though RSI levels suggest overbought conditions. Recent earnings have shown mixed results, beating estimates in Q1 2026 but missing in Q4 2025, while revenue has declined from $14.9B in 2022 to $14.1B in 2025. The company maintains strong profitability with a 21.55% net income margin and recently announced a $0.14 dividend payable in June 2026.
The stock faces headwinds from declining revenue and high valuation multiples (P/E of 30.31), but analyst sentiment remains positive with 56.52% buy ratings. Key risks include freight demand volatility and elevated debt levels. Upside potential exists if operational improvements and margin expansion initiatives succeed, but investors should weigh rich valuations against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →
